Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 4
2006 7
2007 12
2008 9
2009 13
2010 10
2011 13
2012 15
2013 11
2014 11
2015 15
2016 31
2017 27
2018 32
2019 32
2020 48
2021 61
2022 49
2023 46
2024 20

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean efstathiou kastritis (14 results)?
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Pérez-Larraya JG, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL; International Myeloma Working Group. Rodriguez-Otero P, et al. Among authors: kastritis e. Lancet Oncol. 2024 May;25(5):e205-e216. doi: 10.1016/S1470-2045(24)00043-3. Lancet Oncol. 2024. PMID: 38697166 Review.
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, Migkou M, Roussou M, Malandrakis P, Kanellias N, Eleutherakis-Papaiakovou E, Fotiou D, Spiliopoulou V, Gavriatopoulou M, Patel S, Majer I, Boukis C, Fetani A, Dimopoulos MA, Terpos E. Kastritis E, et al. Clin Lymphoma Myeloma Leuk. 2024 Mar 19:S2152-2650(24)00110-1. doi: 10.1016/j.clml.2024.03.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38616479 Free article.
Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.
Jaccard A, Bridoux F, Roeloffzen W, Minnema MC, Bergantim R, Hájek R, João C, Cibeira MT, Palladini G, Schönland S, Merlini G, Milani P, Dimopoulos MA, Ravichandran S, Hegenbart U, Agis H, Gros B, Asra A, Magarotto V, Cheliotis G, Psarros G, Sonneveld P, Wechalekar A, Kastritis E. Jaccard A, et al. Among authors: kastritis e. Clin Lymphoma Myeloma Leuk. 2024 May;24(5):e205-e216. doi: 10.1016/j.clml.2024.01.013. Epub 2024 Feb 1. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38453615
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF. Ghobrial IM, et al. Among authors: kastritis e. Blood Cancer Discov. 2024 May 1;5(3):146-152. doi: 10.1158/2643-3230.BCD-24-0022. Blood Cancer Discov. 2024. PMID: 38441243
Single-cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients.
Bagratuni T, Aktypi F, Theologi O, Sakkou M, Verrou KM, Mavrianou-Koutsoukou N, Patseas D, Liacos C, Skourti S, Papadimou A, Taouxi K, Theodorakakou F, Kollias G, Sfikakis P, Terpos E, Dimopoulos MA, Kastritis E. Bagratuni T, et al. Among authors: kastritis e. Hemasphere. 2024 Feb 8;8(2):e27. doi: 10.1002/hem3.27. eCollection 2024 Feb. Hemasphere. 2024. PMID: 38435423 Free PMC article.
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.
Papatsirou M, Kontos CK, Ntanasis-Stathopoulos I, Malandrakis P, Sideris DC, Fotiou D, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. Papatsirou M, et al. Among authors: kastritis e. Hemasphere. 2024 Jan 26;8(1):e34. doi: 10.1002/hem3.34. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434522 Free PMC article.
A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy.
Asimakopoulou S, Malandrakis P, Kamiliou A, Gavriatopoulou M, Bafa K, Samaras V, Anastasopoulou A, Variami E, Lakiotaki E, Korkolopoulou P, Kastritis E, Dimopoulos MA, Cholongitas E. Asimakopoulou S, et al. Among authors: kastritis e. Leuk Lymphoma. 2024 Feb 28:1-3. doi: 10.1080/10428194.2024.2323084. Online ahead of print. Leuk Lymphoma. 2024. PMID: 38419349 No abstract available.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Soureas K, Papadimitriou MA, Malandrakis P, Papanota AM, Adamopoulos PG, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Sideris DC, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E, Avgeris M. Soureas K, et al. Among authors: kastritis e. Br J Haematol. 2024 Feb 27. doi: 10.1111/bjh.19332. Online ahead of print. Br J Haematol. 2024. PMID: 38414235
411 results